Celecoxib-d7 |
| Catalog No.GC47070 |
An internal standard for the quantification of celecoxib
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 544686-21-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Celecoxib-d7 is intended for use as an internal standard for the quantification of celecoxib by GC- or LC-MS. Celecoxib is a selective inhibitor of COX-2 (IC50s = 22.9 and 0.05 μM for COX-1 and COX-2, respectively).1,2 It displays chemopreventive activity in multiple tumor types via proapoptotic effects that are independent of COX-2 inhibition.3,4,5 Formulations containing celecoxib have been used in the treatment of inflammation while circumventing the gastrointestinal toxicity associated with traditional non-sterodial anti-inflammatory drugs, however, the use of celecoxib has been tempered due to its ability to induce adverse cardiovascular events.6
1.Uddin, J.M., Rao, P.N.P., and Knaus, E.E.Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: Replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostereBioorg. Med. Chem.11(23)5273-5280(2003) 2.Mardini, I.A., and Fitzgerald, G.A.Selective inhibitors of cyclooxygenase-2: A growing class of anti-inflammatory drugsMolecular Interventions1(1)30-38(2001) 3.Jendrossek, V., Handrick, R., and Belka, C.Celecoxib activates a novel mitochondrial apoptosis signaling pathwayThe FASEB Journal171547-1549(2003) 4.Leahy, K.M., Ornberg, R.L., Wang, Y., et al.Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivoCancer Research62625-631(2002) 5.Zhu, J., Huang, J.W., Tseng, P.H., et al.From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitorsCancer Res.644309-4318(2004) 6.Blobaum, A.L., and Marnett, L.J.Structural and functional basis of cyclooxygenase inhibitionJ. Med. Chem.50(7)1425-1441(2007)
| Cas No. | 544686-21-7 | SDF | |
| Canonical SMILES | NS(C1=CC=C(N2C(C3=C([2H])C([2H])=C(C([2H])([2H])[2H])C([2H])=C3[2H])=CC(C(F)(F)F)=N2)C=C1)(=O)=O | ||
| Formula | C17H7D7F3N3O2S | M.Wt | 388.4 |
| Solubility | DMSO: 76 mg/ml,Ethanol: 33 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5747 mL | 12.8733 mL | 25.7467 mL |
| 5 mM | 0.5149 mL | 2.5747 mL | 5.1493 mL |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5747 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *